ZURICH--(BUSINESS WIRE)--Inositec, a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors. Currently CEO of New Amsterdam Pharma, Dr. Davidson was previously the founding CEO and Chief Scientific Officer of Corvidia Therapeutics, which was recently acquired by Novo-Nordisk. He also co-founded Omthera Pharmaceuticals, which was acquired by Astra Zeneca.
ZURICH--(BUSINESS WIRE)--Inositec, a pioneer in the development of life-saving small molecule drugs based on the natural compound inositol hexaphosphate (IP6), announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering its platform of inositol phosphate analogs and specifically INS-3001, an inhibitor of pathological soft tissue calcification. Calcification, particularly in arterial walls and cardiac valves, leads to high cardiovascular morbidity and mortality. Inositec is developing INS-3001 for a number of cardiovascular indications caused by calcification, including aortic valve stenosis. U.S. patent number 10,624,909 covers specifically the composition of matter and use of inositol derivatives for conditions related to pathological calcium crystallization.